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Introduction
Prostate cancer is now the commonest cancer in humans
and the third commonest cancer after breast and lung
cancer; both the frequency and incidence are increasing.
The three main clinical questions are: (1) What is
the extent of prostate cancer when radical surgery is
proposed? (2) Where is the disease when there is a rising
PSA and a normal bone scan and radiology? (3) What
is the significance of a PSA which is in the normal
range but non-zero after radical prostatectomy or radical
radiotherapy? Staging is important. The prognosis falls
from 80% five-year survival to 30% five-year survival if
a single node is involved with prostate cancer.
The imaging questions therefore are: (1) Is the prostate
capsule breached? (2) Is there local node involvement?
(3) Is there extra pelvic node involvement? (4) Is
the skeleton involved? The last question is usually
answered with the methylene diphosphonate (Tc-99m
MDP) bone scan. A recently positive bone scan will
reflect the presence of metastases, whereas a persistently
positive bone scan may represent the healing process
continuing and the effect of hormonal therapy, rather than
persistence of active metastases. Painful bone metastases
may be treated using Strontium 89, or Sm-153 EHMDP
radionuclide therapy [1].
Imaging
After the first suspected detection of prostate cancer
(either by digital rectal examination or screening with
PSA), transrectal ultrasound with multiple biopsies of
the prostate is required. The number of positive biopsies
provides a Gleason score; the higher the Gleason score
the worse the prognosis and the greater the likelihood
of the cancer spreading through the capsule or to local
regional nodes. It is difficult for ultrasound, CT and MRI
to demonstrate capsular involvement and particularly
regional node involvement since involved nodes may not
be enlarged beyond the 1 cm threshold for a ‘normal’
node.
It is clear that cancer cells must be present in a normal-
sized node in order for their multiplication to lead to
an enlarged lymph node. In principle the presence of
malignant cells in a normal-sized node can be determined
by nuclear medicine techniques, since their strength is
identification of cancer cells, as different from normal
cells and the technique does not depend solely on
physical size or contrast. There is a large amplification
factor.
For antigens, there may be between 5000 and 50 000
antigens expressed on a particular cancer cell with which
an appropriate monoclonal antibody radiolabelled with
Tc-99m or Indium-111 can bind. There may be between
5000 and 10 000 receptors on a particular cancer cell with
which a radiolabelled peptide may be chosen to bind.
Most cancer cells have an increased glucose utilisation
and an up-regulation of the glucose-1 transporter protein
by a factor of five to ten and an up-regulation of
the hexokinase enzymes by a factor of two to three.
These enable the use of F-18 deoxyglucose (FDG)
with a positron emission tomography (PET) camera,
whose sensitivity is about 100 times greater than the
conventional gamma camera. These large amplification
factors mean that the radioactive pinhead may be detected
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if it has sufficient radioactivity on it and a sufficiently
sensitive detector. In the context of prostate cancer [2],
glucose utilisation is unfortunately at a low level in the
initial stages (as compared to lung, breast or colon cancer)
and only rapidly progressive metastases of prostate
cancer are reliably FDG positive.
As yet no particular receptors have been identified
as specific to prostate cancer. However, a number of
antigens appear to be prostate cancer specific and
radiolabelled monoclonal antibodies to detect prostate
cancer and demonstrate its potential spread are being
evaluated. Radiolabelled antibodies against PSA and
against plasma acid phosphatase have not been success-
ful, since the avidity of the circulating antigen binds the
injected radiolabelled antibody and no reliable imaging
is obtained of the cancer. This is not however true
for monoclonal antibodies against the prostate specific
membrane antigen (PSMA) whose use is becoming




PSMA, also sometimes called PMSA (prostate mem-
brane specific antigen), is a 100 K Dalton glycopro-
tein antigen related according to different authors to
the transferrin receptor, folate dehydrogenase, and a
neuropeptidase. It is a trans-membrane protein with an
external and internal domain. The intra-cellular domain
has antigens, against which the monoclonal antibody
CYT 356 labelled with Indium-111 is commercially
available as Captomab pendetide (Prostascint, Cytogen
Corporation). It has also been labelled with Tc-99m
called CYT 351, Prostatec [9].
The extra-cellular domain has an antibody developed
by Bander called MUJ-591 which has been radiolabelled
with I-131 [10] and with Tc-99m [11]. Experimental studies
with I-131 or Y-90 radionuclide therapy agents have been
undertaken with both these classes of antibody [12].
Radioimmunoscintigraphy has a number of require-
ments for success. The antigen should be as specific
as possible to the cancer. A monoclonal antibody
should be available with high avidity that binds to this
cancer antigen. It should be radiolabelled with the best
radiolabel: Indium-111 or preferably Tc-99m. The radi-
olabelling method must preserve the antibody’s binding
efficiency. The imaging system must be optimised for the
energy of the radionuclide and the position of the patient.
Single photon emission tomography (SPET) is essential
and image analysis techniques are required.
The rules of radioimmunoscintigraphy are simple.
Specific uptake increases with time so that an image
shortly after the injection of the radiolabelled monoclonal
antibody provides a tumour-free template with which
the later images can be compared. Non-specific uptake
after the initial distribution decreases with time as the
blood level of the agent decreases. The higher the count
rate, the better the detection and the smaller the lesion
detected [13].
Indium-111 anti-PSMA
The product Prostascint (Cytogen Corporation) has been
in use in the United States for several years, with
over 22 000 patient studies, and virtually free of side
effects [4–8]. The imaging protocol requires planar, squat
and SPET studies at 1, 24 and 48 h. The two Indium-
111 peaks at 171 and 252 Kev are summed with 15%
windows. A medium-energy parallel-hole collimator is
used. A 128×128 matrix with 800 Kc for planar imaging,
400 Kc for squat views, and 60 projections (360 degrees,
40 seconds per projection) for SPET. The 1 hour, planar
and SPET images are compared with the later images to
see if a site of specific activity increasing with time is
detected in the prostate, the prostate capsule, the obturator
nodes, pelvic nodes or paraaortic nodes.
Our own experience [14] concerns 49 patients, of whom
36 were untreated primary prostate cancer patients and
13 were for follow-up. Of the 36 patients, 16 had radical
prostatectomy, 17 had radical radiotherapy, of whom
there was extra prostatic disease on the scan in seven, and
three had hormone therapy. Of the 16 patients with radical
prostatectomy, eight had the perineal approach, so no
histology of lymph nodes was obtained, and eight had a
retropubic and lymph node dissection approach. In these
eight patients with nodal histology, none of the nodes
were involved. In six patients, the images of the nodes
were negative, but in two patients there was positive nodal
uptake on imaging. It happened that in those two patients
the surgical margins contained malignancy on histology.
Of the 13 patients who underwent imaging during their
follow-up where there was a rising PSA, 10 patients had
positive immune scans after radical treatment, four with
uptake in the prostate bed and six with pelvic or distant
disease. The three patients receiving hormone therapy
also had positive imaging. The conclusion from this
study was that all localised prostate cancer was imaged
positive; six out of eight immune scan-negative nodes
were negative on histology. 13 out of 13 patients with a
rising PSA had disease localised by the immune scan and
treatment of patients with immune scan-positive sites led
to a fall in PSA [14].
The advantage of Indium-111 as a label is that there
is less bladder activity than with Tc-99m. However, the
disadvantages include the requirement for a longer study
period, more bowel and rectal uptake, more marrow
uptake, a higher effective radiation dose to the patient
and the requirement of the technical procedure to change
from the usual low-energy collimator to a medium-energy
collimator. The use of a thick-crystal camera is preferred.
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Tc-99m labelled anti-PSMA
The antibody used in Prostascint was kindly provided to
us by the Cytogen Corporation for radiolabelling with Tc-
99m. The imaging protocol concerned images at 1, 4 and
24 h together with planar, squat and SPET views. A range
of patients was studied: those with clinically localised
prostate cancer, those in whom prostate cancer was an
incidental finding after transurethral prostatectomy for
prostatic hyperplasia, those who had a rising PSA on
follow-up and some patients with known metastases, in
whom the PSA was rising or falling. The overall accuracy
was 92% and two patients were saved unnecessary
prostatectomy through the demonstration of pelvic and
extra pelvic metastases. Patients with a positive bone scan
and a rising PSA showed uptake in the bone metastases,
however, patients under treatment with bone metastases
seen on the bone scan but with a falling PSA did not show
uptake of the antibody. This probably reflects the bone
scan representing a healing process while still positive,
rather than active disease [9].
Tc-99m MUJ 591
A pilot study of radioimmunoscintigraphy of patients
with prostate cancer, selected for consideration of radical
prostatectomy, was undertaken in 24 patients. All patients
had biopsy evidence of prostate cancer, normal bone
scan and no radiological evidence of extra prostatic
spread. A further four patients were imaged for suspected
progression after prostatectomy. 600 MBq Tc-99m MUJ
591 was injected intravenously with planar, squat and
SPET imaging at about 1 and 24 h. In three patients the
demonstration of extra pelvic disease saved them from
an inappropriate prostatectomy. Nine out of 14 patients
received radical radiotherapy combined with adjuvant
LHRH therapy. Pelvic nodal images were positive in five
but no histological confirmation was possible. Three out
of four patients who underwent imaging for suspected
progression showed disease not detected by bone scan
or by radiological techniques. In summary, all patients
with prostate cancer had the prostate cancer detected
by radioimmunoscintigraphy (28/28). Non-involvement
or obturator and pelvic lymph nodes was confirmed
in 13 to 14 patients who underwent surgery; histology
was obtained. There was one false positive. Disease
progression has occurred in three out of these 14 to
date. Two of the patients were found to have extra pelvic
disease on imaging [11].
This pilot study of prostate cancer and radioim-
munoscintigraphy with Tc-99m MUJ 591 indicated that it
was a promising approach to selecting patients for radical
prostatectomy. In the USA the use of this antibody for
therapy is being investigated, labelled either with I-131
or Y-90 [12] and the antibody has been humanised and has
been licensed to a commercial company.
Conclusion
Monoclonal antibodies against the prostate-specific
membrane antigen whether the external domain (MUJ
591) or the internal domain (CYT 356), labelled with
Tc-99m or with Indium-111, are showing promise in
solving important clinical management problems in
patients with prostate cancer. They aid the determination
of the operability of prostate cancer. They help to
resolve the problem of the slightly raised PSA after
prostatectomy or radical radiotherapy and they are able
to localise the soft tissue cause of a rising PSA in patients
suspected of metastases but with a normal bone scan and
radiology. As these imaging agents become more widely
available so they will affect the general management of
patients with this common cancer [15].
Questions
1. How best to demonstrate that Prostate cancer is
confined to the prostate?
2. How best to evaluate the post radical prostatectomy
or post radical radiotherapy patient who has a
follow up PSA greater than 0.0 but less than 2.0?
3. How best to evaluate the patient with a rising
PSA post primary treatment when bone scan and
radiology are negative?
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